Could steroids beat a deadly lung virus? new trial aims to find out

NCT ID NCT07152600

Not yet recruiting Disease control Sponsor: Qingyuan Zhan Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether adding corticosteroids (methylprednisolone) to standard care can reduce deaths in adults with severe adenovirus pneumonia in the ICU. The study compares low and moderate doses against a placebo (saline). It aims to enroll 262 critically ill patients and will measure survival at 28 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Methylprednisolone (a corticosteroid)

What this could lead to

If it works, this could provide a treatment option to lower the high death rate from severe adenovirus pneumonia.

What could go wrong

This is an early-stage trial with only 262 participants, and corticosteroids may not improve survival or could cause side effects like infections.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOVIRUS INFECTIONS, HUMAN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoviridae infectious disease Community-Acquired Pneumonia pharyngoconjunctival fever

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOVIRUS INFECTIONS, HUMAN